Morepen Labs starts production of test batch of Sputnik V vaccine

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Bavarian Nordic Agrees for a $3 Bn Take-Private Offer

Bavarian Nordic, the vaccine maker, on July 28 said...

South Korea – A Biopharma Innovation Hub With 113% Growth

The biopharmaceutical sector of South Korea has seen a...

Vinay Prasad Leaves the FDA – An Abrupt End to His Tenure

The head of the Food and Drug Administration office,...

Resistance-Evasive Antibiotic for Genes-Free Clinics

In a startling figure, multidrug-resistant bacteria kill almost 5...

Morepen Laboratories has started production of the test batch of Russia’s Sputnik V Covid-19 vaccine at its facility in Himachal Pradesh, Russian Direct Investment Fund (RDIF) and the domestic drug firm said in a statement.

The first batch will be shipped to Gamaleya Center for quality control. RDIF and Morepen Laboratories have signed a cooperation agreement in June 2021 and are actively implementing the technology transfer, it added.

“As the pandemic is yet far from over and new, more dangerous variants of coronavirus are being detected in various regions of the world, RDIF is increasing capacities for the production of Sputnik V in India, one of the key hubs,” RDIF CEO Kirill Dmitriev said.

Agreement with Morepen Laboratories provides for larger amounts of Sputnik V to be available, “both for India and our partners globally to speed up the vaccination with one of the best vaccines in the world,” he added.

RDIF has already reached agreements earlier with other pharmaceutical companies – Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma and Virchow Biotech – in India for the vaccine.

In total, agreements with partners in India provide for the production of more than 850 million doses of Sputnik V per year, the statement said.

https://www.freepressjournal.in/india/morepen-labs-starts-production-of-test-batch-of-sputnik-v-vaccine

Latest stories

Related stories

Bavarian Nordic Agrees for a $3 Bn Take-Private Offer

Bavarian Nordic, the vaccine maker, on July 28 said...

South Korea – A Biopharma Innovation Hub With 113% Growth

The biopharmaceutical sector of South Korea has seen a...

Vinay Prasad Leaves the FDA – An Abrupt End to His Tenure

The head of the Food and Drug Administration office,...

Resistance-Evasive Antibiotic for Genes-Free Clinics

In a startling figure, multidrug-resistant bacteria kill almost 5...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back